Lion (504350) wieder +50% bei nächster Erholung??? - 500 Beiträge pro Seite

[volkerrd]

Was meint Ihr? Hab mir vom Restgeld gerade zu 22€ welche gekauft. Sehen wir 30€ in kurzer Zeit, wenn das Umfeld mal für 2-3 Tage stimmt?

[gemma]

Restrukturierung bei Trega: Belegschaft wird um ca. 20% reduziert.

LION bioscience Builds Chemistry R&D Center of Excellence in San Diego For Software Development and Drug Discovery

Three Key Executives Hired to Accelerate Development of Enterprise-wide Knowledge Management Solution

HEIDELBERG, Germany, April 4

LION bioscience (Nasdaq: LEON; Neuer Markt: LIO, WKN 504 350) today announced it has restructured its San Diego operation to accelerate the integration of its life science informatics expertise gained through the acquisition of Trega Biosciences, Inc. into the existing LION organization. LION will focus on creating an R&D center of excellence in San Diego with extensive knowledge in chemistry, medicinal chemistry and computational sciences. This R&D center will develop predictive software tools for ADME (Absorption, Distribution, Metabolism and Excretion), toxicology and build novel software solutions for cheminformatics in accordance with LION`s goal to revolutionize the way information technology driven drug discovery is conducted in the future. It will also support LION`s internal drug discovery program, iD3(TM). This integration is expected to strongly support the establishment of LION`s integrated horizontal enterprise-wide information and knowledge management solutions -- which combine biology, chemistry and preclinical research with clinical and individual data and information -- as the standard in the market. As part of this restructuring, LION will reduce Trega`s current workforce by approximately 20%.

This integration process will be driven by three new key executives, each with between 10 and 20 years of industry experience, who have joined LION from MDL Information Systems Inc., a leading provider in the field of cheminformatics. Joining LION are: Rudolph Potenzone, Ph.D. as President and Chief Executive Officer of LION`s U.S. operations, Daniel Keesman, Ph.D. as Vice President Global Sales & Marketing, and Mark Canales, Ph.D. as Senior Vice President Cheminformatics Development. Dr. Potenzone replaces Michael G. Grey who has resigned from his position as Chief Executive Officer and President of Trega.

This newly acquired expertise in chemistry and medicinal chemistry augments LION`s already strong expertise in biology, increasing its applicability across the entire R&D chain. Through the recent merger with Trega, and the cooperation with the Gesellschaft fur Medizinische Datenverarbeitung (GMD), announced in February 2001, LION has gained direct access to complimentary software in the preclinical and clinical fields. This range of application modules together with LION`s integration platform SRS, spanning the entire R&D process of the life science industry, forms the foundation for LION`s horizontal, enterprise-wide IT-solutions for the life sciences industry, called i-biology®. These solutions fully support and leverage the users` R&D capabilities and have the potential to significantly accelerate genome-based drug discovery and development.

``Our recent acquisition of Trega as well as our alliances with GMD, Tripos, Inc. and Paradigm Genetics have enabled us to further build and offer comprehensive, horizontally-integrated solutions to meet and support the increasing demands of the Life Sciences industry,`` said Dr. Friedrich von Bohlen, CEO of LION. ``With the appointments of Drs. Potenzone, Keesman and Canales, LION gains recognized experts and managers in the field of chemistry and cheminformatics. Their business experience will allow us to more quickly extend our established in-house expertise in information solutions from biology into preclinical research. As a result, we expect to more rapidly attain our goal of establishing i-biology® as the standard knowledge management solution in the marketplace.``

LION`s activities in cheminformatics started in 1998. In October 2000, LION entered into a landmark $25M pharmacophore arrangement with Bayer pursuant to which LION -- together with Tripos -- is implementing a novel pharmacophore informatics prediction platform for Bayer on a worldwide basis. The recent merger with Trega has extended LION`s in-house expertise into the area of medicinal chemistry, chemical libraries and predictive software for ADME/toxicology. The appointments of Drs. Potenzone, Keesman and Canales underline LION`s long-term objective to provide horizontally-integrated, enterprise-wide information systems to accelerate and improve R&D quality and performance.

Dr. Rudolph Potenzone, formerly Senior Vice President for Marketing & Development at MDL, heads LION`s U.S. operations. With more than 20 years of cheminformatics experience, Potenzone most recently worked at MDL where he managed the design, development and marketing of the company`s software and database products. Previously, Dr. Potenzone was Director of Research and New Product Development at Chemical Abstracts Service (CAS), and, prior to CAS, at Polygen/Molecular Simulations, Inc. Dr. Potenzone brings over ten years of industrial experience managing chemical information systems. He holds a Ph.D. in macromolecular science from Case Western Reserve University in Cleveland, Ohio and a bachelor of science degree in biophysics and microbiology from the University of Pittsburgh.

Dr. Daniel Keesman has been appointed as Global Vice President, Sales & Marketing for LION bioscience, Inc. While at MDL, he served as Vice President for MDL Europe and Managing Director of MDL Frankfurt, responsible for all of MDL`s operations and business within Europe. Previously, he had served in different positions at MDL, including as Director of Professional Services Europe, in charge of the implementation of multi-national projects for Discovery Informatics. He received his Ph.D. and diploma in chemistry from the University of Stuttgart. In his new position at LION, Dr. Keesman will be responsible for directing LION`s business strategy and initiatives and for leading LION`s sales and services organization. He will be based in Heidelberg, Germany.

Dr. Mark Canales, formerly Vice President of Product Development at MDL, has been appointed as Senior Vice President Cheminformatics Development for LION`s U.S. operations. Dr. Canales will be responsible for integrating cheminformatics product development with bioinformatics product development at LION. Dr. Canales has over 17 years experience in the design and development of software and hardware solutions for the scientific market. He has successfully managed multiple projects with multinational development groups spread across multiple sites. In the past, Dr. Canales also acted as director of product development at ThermoQuest Corporation`s Finnigan Corporation subsidiary. Prior to joining Finnigan, Dr. Canales worked with PE Nelson Systems (formerly Nelson Analytical) where he led both software and hardware programs within the Desktop DataSystems Group. Dr. Canales holds a Ph.D. in biochemistry from the University of Minnesota. His undergraduate degrees are an A.B. in philosophy and B.S. in chemistry from Gonzaga University.

About Cheminformatics:

Cheminformatics involves the combination of chemistry and computation, and is the management of data, information and knowledge of chemical compounds and their measured properties, such as biological activity. When used in drug discovery, it helps chemists choose which new compounds should be synthesized from the almost infinite number of possible molecular structures. Cheminformatics advances are playing an essential role in generating, selecting and optimizing qualified drug leads from the increasing amount of potential drug targets.

About LION bioscience AG:

LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genetics to early and late discovery through clinical trials. LION offers these solutions via two primary lines of business:

i-biology®: the installation and implementation of enterprise-wide horizontal information and knowledge management solutions as part of LION`s Life Science Informatics (LSI(TM)) line of business; and
Integrated Drug Discovery and Diagnostics (iD3(TM)): application of i-biology® to LION`s internal drug discovery program with the goal to out-license specific databases, polymorphism marker panels, and validated targets and leads.
Founded in 1997, LION, together with its consolidated subsidiaries, has more than 440 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA, and as a result of the Trega acquisition, San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, Glaxo Wellcome, GMD, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, SmithKline Beecham, Sumitomo Pharmaceuticals and Tripos.

All statements in this press release that are not historical are forward-looking statements within the meaning of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such as uncertainties relating to technologies, product development, or manufacturing, market acceptance, cost or pricing of LION`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent protection and litigation. These and other risk factors are discussed in LION`s Registration Statement on Form F-4 declared effective by the SEC on February 9, 2001. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein.

LION bioscience®, SRS, SRS 6.1 and i-biology® are either registered trademarks of LION bioscience AG in the United States and/or other countries, or LION bioscience AG has pending applications for these trademarks in the United States and/or other countries. The names of other actual companies and products mentioned herein may be the trademark of their respective owners. Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in the United States. Trega® is a registered trademark of Trega Biosciences, Inc.


CONTACT:

LION bioscience
Dr. Andrea Kreisselmeier
Director Corporate Marketing & Communications
[phone]
andrea.kreisselmeier@lionbioscience

Noonan/Russo Communications
Matthew Scampoli
[phone] ext. 243
[e-mail]

SOURCE: LION bioscience

[timekiller]

Wieso steigen die?
Sehr ärgerlich, bin heut morgen raus...


Grüsse

[volkerrd]

tja, schade.
Ist mir auch manchmal so gegangen, ich bin auch raus, aber heute mit 40% Gewinn. Die Verlockung nach 2Tagen war einfach zu gross, wenns morgen weiterläuft, ok, ist dann so. Aber realisierte Gewinne müssen auch mal sein.
Tschau

[Kanthak]

Wer kann mir sagen, wo ich den Kurs für das US-Unternehmen United Biomedical finden kann.Diese Firma hat einen Test entwickelt, der Eiweißkörper nachweist, die nur in von MKS-infizierten Tieren entstehen. Dieser ist jedoch noch nicht zugelassen. Sollte dies geschehen, ´wäre die Aktie sehr interessant. Es ist mir nicht gelungen, über US-Finanzseiten die Namenskürzel auszumachen. Kanthak